It is important to note that TLR4/NF-κB signaling strengthens the fibrogenic pathway of TGF-β (46), and its suppression is considered a therapeutic target in liver fibrosis (13, 25, 47). This evidence concerns the gene TGFB1 and Hepatic fibrosis.